Literature DB >> 8075648

Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.

N Bardeesy1, D Falkoff, M J Petruzzi, N Nowak, B Zabel, M Adam, M C Aguiar, P Grundy, T Shows, J Pelletier.   

Abstract

The genetics of Wilms' tumour (WT), a paediatric malignancy of the kidney, is complex. Inactivation of the tumour suppressor gene, WT1, is associated with tumour aetiology in approximately 10-15% of WTs. Chromosome 17p changes have been noted in cytogenetic studies of WTs, prompting us to screen 140 WTs for p53 mutations. When histopathology reports were available, p53 mutations were present in eight of eleven anaplastic WTs, a tumour subtype associated with poor prognosis. Amplification of MDM2, a gene whose product binds and sequesters p53, was excluded. Our results indicate that p53 alterations provide a molecular marker for anaplastic WTs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075648     DOI: 10.1038/ng0594-91

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  70 in total

Review 1.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Authors:  Richard D Williams; Reem Al-Saadi; Tasnim Chagtai; Sergey Popov; Boo Messahel; Neil Sebire; Manfred Gessler; Jenny Wegert; Norbert Graf; Ivo Leuschner; Mike Hubank; Chris Jones; Gordan Vujanic; Kathy Pritchard-Jones
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

3.  Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.

Authors:  Raisa Vuononvirta; Neil J Sebire; Anthony R Dallosso; Jorge S Reis-Filho; Richard D Williams; Alan Mackay; Kerry Fenwick; Anita Grigoriadis; Alan Ashworth; Kathy Pritchard-Jones; Keith W Brown; Gordan M Vujanic; Chris Jones
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 4.  Genomics of adult and pediatric solid tumors.

Authors:  Zahraa Rahal; Farah Abdulhai; Humam Kadara; Raya Saab
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 5.  Metanephric adenofibroma in a 10-year-old boy: report of a case and review of the literature.

Authors:  Dong-Wei Yao; Feng Qu; Su-Wei Hu; Jin-Yu Zheng; Jin-Mei Wang; Xiang-Yu Zhu; Jie Li; Hong-Qian Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

6.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

7.  A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1.

Authors:  R W Johnstone; R H See; S F Sells; J Wang; S Muthukkumar; C Englert; D A Haber; J D Licht; S P Sugrue; T Roberts; V M Rangnekar; Y Shi
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

8.  Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.

Authors:  Najat C Daw; Yueh-Yun Chi; Yeonil Kim; Elizabeth A Mullen; John A Kalapurakal; Jing Tian; Geetika Khanna; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Anne B Warwick; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal:  Eur J Cancer       Date:  2019-07-17       Impact factor: 9.162

Review 9.  Lessons from the p53 mutant mouse.

Authors:  T Jacks
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

10.  Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Stephen Qualman; James Lynch; Julia Bridge; David Parham; Lisa Teot; William Meyer; Alberto Pappo
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.